E.W. Scripps Seeks Shareholder Ratification for Poison Pill Amidst CEO's $10M Performance Award
Summary
E.W. Scripps is seeking shareholder ratification for a defensive Shareholder Rights Plan and detailing its CEO's new $10 million performance-based compensation package, alongside proposals for director elections at its upcoming annual meeting.
Key Events
-
Shareholder Rights Plan Ratification
The company is seeking shareholder ratification for a Shareholder Rights Plan (poison pill) adopted on November 25, 2025, following an unsolicited acquisition proposal. The plan's exercise price is $2.19, and it includes a 'flip-in' trigger allowing non-acquiring shareholders to purchase shares at a discount if a person or group acquires 10% or more of outstanding Class A Common Shares. The plan will expire if not ratified at the 2026 annual meeting.
-
CEO Employment Agreement and Performance Award
Details of the CEO's extended employment agreement through December 31, 2029, are provided, including an annual base salary of at least $1.4 million and a target long-term incentive of at least $4.7 million for 2026. A one-time $10 million performance-based cash award is included, vesting based on EBITDA growth targets and a $10.00 stock price hurdle by December 31, 2029. This follows the 8-K filing on 2026-02-26.
-
Board Expansion and Director Nominee
The Board voted in February 2026 to increase its size from 11 to 12 directors, effective at the annual meeting. A new nominee, Tracy Ward, is proposed, whose qualifications and connection to the Scripps family's institutional knowledge are cited as reasons for the expansion.
-
Executive Compensation Details
The filing outlines the 2025 compensation for named executive officers, including base salaries, short-term incentives (STI), and long-term incentives (LTI). The CEO's total compensation for 2025 was $7.24 million, and average for other NEOs was $2.68 million. STI payouts for 2025 were 88-90% of target based on operating cash flow and revenue goals.
Analysis
This preliminary proxy statement details key proposals for the upcoming annual meeting, including the ratification of a Shareholder Rights Plan (poison pill) adopted in November 2025 following an unsolicited acquisition proposal. This defensive measure, with an exercise price of $2.19 (below current market price), aims to protect shareholders from coercive tactics and provide the board leverage in potential M&A. The filing also provides full details on the CEO's recently extended employment agreement, which includes a $10 million performance-based cash award tied to a $10 stock price target and EBITDA growth, a significant compensation package given the company's recent net losses. The board is also proposing to increase its size from 11 to 12 directors, adding a nominee with ties to the Scripps family's institutional knowledge. Investors should monitor the outcome of the rights plan ratification and its implications for potential M&A activity, as well as the company's ability to meet the ambitious performance targets set for executive compensation.
At the time of this filing, SSP was trading at $4.63 on NASDAQ in the Technology sector, with a market capitalization of approximately $409.5M. The 52-week trading range was $1.36 to $4.98. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.